Difference between revisions of "Team:DTU-Denmark/Description"
| (29 intermediate revisions by 7 users not shown) | |||
| Line 18: | Line 18: | ||
<div class="container-fluid"> | <div class="container-fluid"> | ||
<div class="row"> | <div class="row"> | ||
| − | <div class="col-md-12 thumbnail" style="background-image:url(https:// | + | <div class="col-md-12 thumbnail" style="background-image:url(https://static.igem.org/mediawiki/2016/5/56/T--DTU-Denmark--project-header.jpg)"> <!-- EDIT style url (this should lead to an image) --> |
<div class="caption"> | <div class="caption"> | ||
<div class="col-md-5 col-sm-5 col-xs-12 title"> <!-- the approximate max number of characters ~ 400 --> <!-- EDIT --> | <div class="col-md-5 col-sm-5 col-xs-12 title"> <!-- the approximate max number of characters ~ 400 --> <!-- EDIT --> | ||
| − | <h1> | + | <h1>Parts<p class="lead">We have constructed four new basic parts, 4 composite parts, a plasmid backbone and improved two parts made by a previous team. The parts are all a part of our molecular toolbox for protein expression in <i>Yarrowia lipolytica</i>. </p></h1> |
| − | + | ||
</div> | </div> | ||
<div class="col-md-2 col-sm-2 hidden-xs space"></div> | <div class="col-md-2 col-sm-2 hidden-xs space"></div> | ||
<div class="col-md-5 col-sm-5 hidden-xs intro"> <!-- will be hidden on phones, duplicate the text to blockquote down below first section header, to show it there, when it dissapear--> | <div class="col-md-5 col-sm-5 hidden-xs intro"> <!-- will be hidden on phones, duplicate the text to blockquote down below first section header, to show it there, when it dissapear--> | ||
<blockquote class="blockquote-reverse"> <!-- EDIT --> | <blockquote class="blockquote-reverse"> <!-- EDIT --> | ||
| − | <p> | + | <p>"A great building will never stand if you neglect the small bricks"</p> |
| − | <small> | + | <small>Ifeanyi Enoch Onuoha<cite title="Source Title"></cite></small> |
</blockquote> | </blockquote> | ||
</div> | </div> | ||
| Line 45: | Line 44: | ||
<div class="col-md-9 col-sm-10 colLeft"> <!-- LEFT --> | <div class="col-md-9 col-sm-10 colLeft"> <!-- LEFT --> | ||
<div><a class="anchor" id="section-1"></a> | <div><a class="anchor" id="section-1"></a> | ||
| − | + | <h2 class="h2">Parts list</h2> | |
<blockquote class="visible-xs"> <!-- quote from masterhead duplicate --> | <blockquote class="visible-xs"> <!-- quote from masterhead duplicate --> | ||
| − | <p> | + | <p>"A great building will never stand if you neglect the small bricks"</p> |
| − | <small> | + | <small>Ifeanyi Enoch Onuoha<cite title="Source Title"></cite></small> |
</blockquote> | </blockquote> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
<div class="grid-row"> | <div class="grid-row"> | ||
| Line 187: | Line 65: | ||
</div> | </div> | ||
<div class="col-md-9 col-sm-9 col-xs-12"> | <div class="col-md-9 col-sm-9 col-xs-12"> | ||
| − | <p> | + | <p>hrGFP codon-optimized for <i>Yarrowia lipolytica</i></p> |
</div> | </div> | ||
</div> <!-- /grid-row --> | </div> <!-- /grid-row --> | ||
| Line 196: | Line 74: | ||
</div> | </div> | ||
<div class="col-md-9 col-sm-9 col-xs-12"> | <div class="col-md-9 col-sm-9 col-xs-12"> | ||
| − | <p>Composite part consisting of the TEF1 promoter and the human proinsulin gene</p> | + | <p>Composite part consisting of the TEF1 promoter and the human proinsulin gene codon-optimized for <i>Y. lipolytica</i></p> |
</div> | </div> | ||
</div> <!-- /grid-row --> | </div> <!-- /grid-row --> | ||
| Line 205: | Line 83: | ||
</div> | </div> | ||
<div class="col-md-9 col-sm-9 col-xs-12"> | <div class="col-md-9 col-sm-9 col-xs-12"> | ||
| − | <p> | + | <p>Human proinsulin codon-optimized for <i>Y. lipolytica</i></p> |
</div> | </div> | ||
</div> <!-- /grid-row --> | </div> <!-- /grid-row --> | ||
| Line 214: | Line 92: | ||
</div> | </div> | ||
<div class="col-md-9 col-sm-9 col-xs-12"> | <div class="col-md-9 col-sm-9 col-xs-12"> | ||
| − | <p> | + | <p>SCR1'-tRNA promoter expressing sgRNA</p> |
</div> | </div> | ||
</div> <!-- /grid-row --> | </div> <!-- /grid-row --> | ||
| − | + | ||
<div class="grid-row"> | <div class="grid-row"> | ||
<div class="col-md-3 col-sm-3 col-xs-12"> | <div class="col-md-3 col-sm-3 col-xs-12"> | ||
| Line 223: | Line 101: | ||
</div> | </div> | ||
<div class="col-md-9 col-sm-9 col-xs-12"> | <div class="col-md-9 col-sm-9 col-xs-12"> | ||
| − | <p> | + | <p>hrGFP expressed by the constitutive TEF1 promoter</p> |
</div> | </div> | ||
</div> <!-- /grid-row --> | </div> <!-- /grid-row --> | ||
| Line 238: | Line 116: | ||
<div class="grid-row"> | <div class="grid-row"> | ||
<div class="col-md-3 col-sm-3 col-xs-12"> | <div class="col-md-3 col-sm-3 col-xs-12"> | ||
| − | <a href="http://parts.igem.org/Part: | + | <a href="http://parts.igem.org/Part:BBa_K2117010">BBa_K2117010</a> |
</div> | </div> | ||
<div class="col-md-9 col-sm-9 col-xs-12"> | <div class="col-md-9 col-sm-9 col-xs-12"> | ||
| Line 250: | Line 128: | ||
</div> | </div> | ||
<div class="col-md-9 col-sm-9 col-xs-12"> | <div class="col-md-9 col-sm-9 col-xs-12"> | ||
| − | <p>Composite part of TEF1 and | + | <p>Composite part of TEF1 and enhanced CFP</p> |
</div> | </div> | ||
</div> <!-- /grid-row --> | </div> <!-- /grid-row --> | ||
| Line 259: | Line 137: | ||
</div> | </div> | ||
<div class="col-md-9 col-sm-9 col-xs-12"> | <div class="col-md-9 col-sm-9 col-xs-12"> | ||
| − | <p>Improved | + | <p>Improved <a href="http://parts.igem.org/Part:BBa_K530001">BBa_K530001</a> (<em>crtE</em>)</p> |
</div> | </div> | ||
</div> <!-- /grid-row --> | </div> <!-- /grid-row --> | ||
| Line 268: | Line 146: | ||
</div> | </div> | ||
<div class="col-md-9 col-sm-9 col-xs-12"> | <div class="col-md-9 col-sm-9 col-xs-12"> | ||
| − | <p>Improved | + | <p>Improved <a href="http://parts.igem.org/Part:BBa_K530002">BBa_K530002</a> (<em>crtI</em>)</p> |
</div> | </div> | ||
</div> <!-- /grid-row --> | </div> <!-- /grid-row --> | ||
| + | |||
| + | </div> <!-- /overview--> | ||
| + | |||
| + | <div><a class="anchor" id="section-2"></a> | ||
| + | <h2 class="h2">Improvement and Characterization of Two Existing Parts</h2> | ||
| + | <p> | ||
| + | In our laboratory work, we wanted to work with the two BioBricks; <a href="http://parts.igem.org/Part:BBa_K530001">BBa_K530001</a> (<em>crtE</em> gene) and <a href="http://parts.igem.org/Part:BBa_K530002">BBa_K530002</a> (<em>crtI</em> gene) created by the John Hopkins iGEM team 2011. The genes encode the two enzymes Geranylgeranyl Diphosphate Synthase and Phytoene Desaturase, respectively, both from the wildtype strain of <i>xanthophyllomyces dendrorhous</i> used in the biosynthesis of beta-Carotene. | ||
| + | </p> | ||
| + | |||
| + | <p> | ||
| + | When looking into the specifications of these BioBricks, we realized that both genes contained illegal restriction sites. | ||
| + | </p> | ||
| + | <p> | ||
| + | <a href="http://parts.igem.org/Part:BBa_K530001">BBa_K530001</a> contained an AgeI restriction site making the part incompatible with the RFC25 Freiburg Standard. The RFC25 standard allows for in-frame assembly of protein domains. | ||
| + | <a href="http://parts.igem.org/Part:BBa_K530002">BBa_K530002</a> contained the illegal restriction site BglII making the part incompatible with the RFC21 Berkely Standard, which enables in-frame assembly of proteins. | ||
| + | </p> | ||
| + | |||
| + | <p> | ||
| + | We wanted to overcome these obstacle by removing the illegal restriction sites from the above described Biobricks. | ||
| + | </p> | ||
| + | |||
| + | <h3 class="h3">How did we do it?</h3> | ||
<p> | <p> | ||
| − | + | The illegal restriction sites were removed using site directed mutagenesis with primers containing nucleotide substitutions in the two restriction sites (see Figure 1). | |
</p> | </p> | ||
| − | |||
| − | + | <figure class="figure"> | |
| − | + | <img id="img1" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/9/97/T--DTU-Denmark--sitedirected.png" alt="DESCRIPTION"> | |
| + | <figcaption class="figure-caption"><strong>Figure 1:</strong> Primers overlapping the restriction sites are designed with a single nucleotide change to disrupt the restriction site. The primers anneal to the template plasmid and replicate while introducing the point mutation. The elongated plasmids are digested with the enzyme DpnI, which cleaves at the methylated sites breaking down the circular template, resulting in a higher transformation efficiency of the linear PCR product. </figcaption> | ||
| + | </figure> | ||
| + | |||
| + | <!-- The Modal with same picture--> | ||
| + | <div id="img1Modal" class="modal"> | ||
| + | <span class="close img1">×</span> | ||
| + | <img class="modal-content" id="img1Img"> | ||
| + | <div class="caption">DESCRIPTION</div> | ||
| + | </div> | ||
| + | |||
| + | |||
| + | <figure class="figure"> | ||
| + | <img id="img2" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/c/cc/T--DTU-Denmark--primers.jpg" alt="DESCRIPTION"> | ||
| + | <figcaption class="figure-caption"><strong>Table 1:</strong> Primers designed for removal of illegal restriction sites. Bold marks the nucleotide substitution.</figcaption> | ||
| + | </figure> | ||
| + | |||
| + | <!-- The Modal with same picture--> | ||
| + | <div id="img2Modal" class="modal"> | ||
| + | <span class="close img2">×</span> | ||
| + | <img class="modal-content" id="img2Img"> | ||
| + | <div class="caption">DESCRIPTION</div> | ||
| + | </div> | ||
| + | |||
| + | <p> | ||
| + | The new plasmid, <a href="http://parts.igem.org/Part:BBa_K2117012">BBa_K2117012</a>, with the removed AgeI restriction site was double digested with the enzyme and SpeI to test if we had successfully removed the AgeI restriction site. | ||
| + | </p> | ||
| + | |||
| + | <div class="row"> | ||
| + | <div class="col-md-6 col-sm-6"> | ||
| + | <figure class="figure"> | ||
| + | <img width="400" id="img3" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/5/55/T--DTU-Denmark--digest1.jpg" alt="DESCRIPTION"> | ||
| + | <figcaption class="figure-caption"><strong>Figure 2:</strong> AgeI + SpeI digestion. Electrophoresis on a 1% agarose gel showing the digestion of <a href="http://parts.igem.org/Part:BBa_K2117012">BBa_K2117012</a> (lane 1-3). <a href="http://parts.igem.org/Part:BBa_K530001">BBa_K530001</a> digested with AgeI + SpeI and undigested <a href="http://parts.igem.org/Part:BBa_K530001">BBa_K530001</a> were used as controls (lane 4+5). </figcaption> | ||
| + | </figure> | ||
| + | |||
| + | <!-- The Modal with same picture--> | ||
| + | <div id="img3Modal" class="modal"> | ||
| + | <span class="close img3">×</span> | ||
| + | <img class="modal-content" id="img3Img"> | ||
| + | <div class="caption">DESCRIPTION</div> | ||
| + | </div> | ||
| + | </div> | ||
| + | <div class="col-md-6 col-sm-6"><p style="color:transparent;"> h</p></div> | ||
| + | </div> | ||
| + | |||
| + | |||
<p> | <p> | ||
| − | + | The digestion showed the removal of the AgeI restriction site, shown on the gel picture by only one band on the <a href="http://parts.igem.org/Part:BBa_K2117012">BBa_K2117012</a> compared to two bands on the control <a href="http://parts.igem.org/Part:BBa_K530001">BBa_K530001</a>. | |
</p> | </p> | ||
| − | |||
| − | |||
| − | |||
<p> | <p> | ||
| − | + | <a href="http://parts.igem.org/Part:BBa_K2117012">BBa_K2117012</a> and <a href="http://parts.igem.org/Part:BBa_K2117013">BBa_K2117013</a> were sent for sequencing with the verification primers VR and VF2 primers to further verify the removal of the restriction sites. | |
</p> | </p> | ||
| − | |||
| − | + | <div class="row"> | |
| − | + | <div class="col-md-12"> | |
| + | <figure class="figure"> | ||
| + | <img id="img4" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/9/9c/T--DTU-Denmark--AgeI.JPG" alt="DESCRIPTION"> | ||
| + | <figcaption class="figure-caption"><strong>Figure 3:</strong> Sequencing alignment of BBa_530001 (top sequence) and <a href="http://parts.igem.org/Part:BBa_K2117012">BBa_K2117012</a> (bottom sequence). The alignment shows a nucleotide substitution in the AgeI restriction site. </figcaption> | ||
| + | </figure> | ||
| + | |||
| + | <!-- The Modal with same picture--> | ||
| + | <div id="img4Modal" class="modal"> | ||
| + | <span class="close img4">×</span> | ||
| + | <img class="modal-content" id="img4Img"> | ||
| + | <div class="caption">DESCRIPTION</div> | ||
| + | </div> | ||
| + | </div> | ||
| + | |||
| + | <div class="col-md-12"> | ||
| + | <figure class="figure"> | ||
| + | <img id="img5" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/a/ad/T--DTU-Denmark--BglII.jpg" alt="DESCRIPTION"> | ||
| + | <figcaption class="figure-caption"><strong>Figure 4:</strong> Sequencing alignment of BBa_530002 (top sequence) and <a href="http://parts.igem.org/Part:BBa_K2117013">BBa_K2117013</a> (bottom sequence). The alignment shows a nucleotide substitution in the BglII restriction site. </figcaption> | ||
| + | </figure> | ||
| + | <!-- The Modal with same picture--> | ||
| + | <div id="img5Modal" class="modal"> | ||
| + | <span class="close img5">×</span> | ||
| + | <img class="modal-content" id="img5Img"> | ||
| + | <div class="caption">DESCRIPTION</div> | ||
| + | </div> | ||
| + | </div> | ||
| + | |||
| + | </div> | ||
| + | |||
| + | |||
<p> | <p> | ||
| − | + | The sequencing results show a substitution in the restriction sites corresponding to the nucleotide substitution designed in the primers (Table 1). | |
</p> | </p> | ||
| − | |||
| − | |||
| − | |||
<p> | <p> | ||
| − | + | By deleting the two restriction sites in the <a href="http://parts.igem.org/Part:BBa_K2117012">BBa_K2117012</a> and <a href="http://parts.igem.org/Part:BBa_K2117013">BBa_K2117013</a> we have made the two BioBricks compatible with RFC25 and RFC21 standards, respectively. | |
| + | </p> | ||
| + | |||
| + | <h3 class="h3">Improvement of Characterization</h3> | ||
| + | |||
| + | <p> | ||
| + | While working with <a href="http://parts.igem.org/Part:BBa_K530001">BBa_K530001</a> and <a href="http://parts.igem.org/Part:BBa_K530002">BBa_K530002</a> we were struggling with assembly of the genes. Therefore, we sequenced the plasmids received in the distribution kit. | ||
| + | </p> | ||
| + | |||
| + | <p> | ||
| + | Sequencing results of <a href="http://parts.igem.org/Part:BBa_K530002">BBa_K530002</a> showed nucleotide substitutions in the prefix and a large deletion in the suffix. | ||
| + | </p> | ||
| + | |||
| + | <figure class="figure"> | ||
| + | <img id="img6" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/b/b5/T--DTU-Denmark--prefix.png" alt="DESCRIPTION"> | ||
| + | <figcaption class="figure-caption"><strong>Figure 5:</strong> Alignment of <a href="http://parts.igem.org/Part:BBa_K530002">BBa_K530002</a> sequence received from the parts page (top) and sequencing results of <a href="http://parts.igem.org/Part:BBa_K530002">BBa_K530002</a> from the distribution kit. Alignment shows many nucleotide substitutions in the prefix seuqence. </figcaption> | ||
| + | </figure> | ||
| + | |||
| + | <div id="img6Modal" class="modal"> | ||
| + | <span class="close img6">×</span> | ||
| + | <img class="modal-content" id="img6Img"> | ||
| + | <div class="caption">DESCRIPTION</div> | ||
| + | </div> | ||
| + | |||
| + | <figure class="figure"> | ||
| + | <img id="img7" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/e/e2/T--DTU-Denmark--suffix.png" alt="DESCRIPTION"> | ||
| + | <figcaption class="figure-caption"><strong>Figure 6:</strong> Alignment of <a href="http://parts.igem.org/Part:BBa_K530002">BBa_K530002</a> sequence received from the parts page (top) and sequencing results of <a href="http://parts.igem.org/Part:BBa_K530002">BBa_K530002</a> from the distribution kit. Alignment shows a deletion in the suffix sequence. </figcaption> | ||
| + | </figure> | ||
| + | |||
| + | <div id="img7Modal" class="modal"> | ||
| + | <span class="close img7">×</span> | ||
| + | <img class="modal-content" id="img7Img"> | ||
| + | <div class="caption">DESCRIPTION</div> | ||
| + | </div> | ||
| + | |||
| + | <p> | ||
| + | The alterations in prefix and suffix make the <a href="http://parts.igem.org/Part:BBa_K530002">BBa_K530002</a> incompatible with the BioBrick standard | ||
</p> | </p> | ||
</div> | </div> | ||
| + | |||
| + | |||
| + | |||
</div> <!-- /LEFT --> | </div> <!-- /LEFT --> | ||
| Line 311: | Line 316: | ||
<div class="col-md-3 col-sm-2 colRight" id="scrollspy"> | <div class="col-md-3 col-sm-2 colRight" id="scrollspy"> | ||
<ul class="nav" id="sidebar"> | <ul class="nav" id="sidebar"> | ||
| − | <li><a href="#section-1 | + | <li><a href="#section-1">Parts list</a></li> |
| − | + | <li><a href="#section-2">Improvement and Characterization</a></li> | |
| − | <li><a href="#section- | + | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
</ul> | </ul> | ||
</div> <!-- /RIGHT --> | </div> <!-- /RIGHT --> | ||
Latest revision as of 02:05, 20 October 2016
Parts
We have constructed four new basic parts, 4 composite parts, a plasmid backbone and improved two parts made by a previous team. The parts are all a part of our molecular toolbox for protein expression in Yarrowia lipolytica.
Parts list
"A great building will never stand if you neglect the small bricks"
Ifeanyi Enoch Onuoha
Constitutive TEF1 promoter
hrGFP codon-optimized for Yarrowia lipolytica
Composite part consisting of the TEF1 promoter and the human proinsulin gene codon-optimized for Y. lipolytica
Human proinsulin codon-optimized for Y. lipolytica
SCR1'-tRNA promoter expressing sgRNA
hrGFP expressed by the constitutive TEF1 promoter
Semi-synthetic shuttle vector pSB1A8YL
Composite part of TEF1 and enhanced YFP
Composite part of TEF1 and enhanced CFP
Improved BBa_K530001 (crtE)
Improved BBa_K530002 (crtI)
Improvement and Characterization of Two Existing Parts
In our laboratory work, we wanted to work with the two BioBricks; BBa_K530001 (crtE gene) and BBa_K530002 (crtI gene) created by the John Hopkins iGEM team 2011. The genes encode the two enzymes Geranylgeranyl Diphosphate Synthase and Phytoene Desaturase, respectively, both from the wildtype strain of xanthophyllomyces dendrorhous used in the biosynthesis of beta-Carotene.
When looking into the specifications of these BioBricks, we realized that both genes contained illegal restriction sites.
BBa_K530001 contained an AgeI restriction site making the part incompatible with the RFC25 Freiburg Standard. The RFC25 standard allows for in-frame assembly of protein domains. BBa_K530002 contained the illegal restriction site BglII making the part incompatible with the RFC21 Berkely Standard, which enables in-frame assembly of proteins.
We wanted to overcome these obstacle by removing the illegal restriction sites from the above described Biobricks.
How did we do it?
The illegal restriction sites were removed using site directed mutagenesis with primers containing nucleotide substitutions in the two restriction sites (see Figure 1).
×
![]()
DESCRIPTION
×
![]()
DESCRIPTION
The new plasmid, BBa_K2117012, with the removed AgeI restriction site was double digested with the enzyme and SpeI to test if we had successfully removed the AgeI restriction site.
×
![]()
DESCRIPTION
h
The digestion showed the removal of the AgeI restriction site, shown on the gel picture by only one band on the BBa_K2117012 compared to two bands on the control BBa_K530001.
BBa_K2117012 and BBa_K2117013 were sent for sequencing with the verification primers VR and VF2 primers to further verify the removal of the restriction sites.
×
![]()
DESCRIPTION
×
![]()
DESCRIPTION
The sequencing results show a substitution in the restriction sites corresponding to the nucleotide substitution designed in the primers (Table 1).
By deleting the two restriction sites in the BBa_K2117012 and BBa_K2117013 we have made the two BioBricks compatible with RFC25 and RFC21 standards, respectively.
Improvement of Characterization
While working with BBa_K530001 and BBa_K530002 we were struggling with assembly of the genes. Therefore, we sequenced the plasmids received in the distribution kit.
Sequencing results of BBa_K530002 showed nucleotide substitutions in the prefix and a large deletion in the suffix.
×
![]()
DESCRIPTION
×
![]()
DESCRIPTION
The alterations in prefix and suffix make the BBa_K530002 incompatible with the BioBrick standard
